
## Jiaxue Wang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7079899/publications.pdf Version: 2024-02-01



LIAVUE MANC

#	Article	IF	CITATIONS
1	Pharmacokinetic bioequivalence, safety, and immunogenicity of GB222, a bevacizumab biosimilar candidate, and bevacizumab in Chinese healthy males: a randomized clinical trial. Expert Opinion on Biological Therapy, 2022, 22, 253-262.	1.4	2
2	rHuPH20-facilitated subcutaneous administration of monoclonal antibodies in cancer therapy. Immunotherapy, 2021, 13, 79-88.	1.0	0
3	A Systematic Review and Meta-Analysis: Safety and Efficacy of Mesenchymal Stem Cells Therapy for Heart Failure. Current Stem Cell Research and Therapy, 2021, 16, 354-365.	0.6	14
4	Comparative efficacy and safety of 8 GLP-1RAs in patients with type 2 diabetes: A network meta-analysis. Diabetes Research and Clinical Practice, 2021, 177, 108904.	1.1	17
5	A randomized phase I clinical trial comparing the pharmacokinetic, safety, and immunogenicity of potential biosimilar recombinant human HER2 monoclonal antibody for injection and trastuzumab in healthy Chinese adults. Expert Opinion on Investigational Drugs, 2020, 29, 755-762.	1.9	8
6	A Randomized Study on the Bioequivalence of Desloratadine in Healthy Chinese Subjects and the Association of Different Metabolic Phenotypes With UGT2B10 and CYP2C8 Genotypes. Current Drug Metabolism, 2020, 21, 1031-1039.	0.7	1
7	Randomised, double-blind, multicentre, phase â/â¡ dose escalation and expansion trial of CR1501 in patients with plaque psoriasis: study protocol. BMJ Open, 2020, 10, e039067.	0.8	1
8	The long-term efficacy of cytokine-induced killer cellular therapy for hepatocellular carcinoma: a meta-analysis. Immunotherapy, 2019, 11, 1325-1335.	1.0	6
9	A randomized controlled dose-escalation study of SSS07, a humanized rabbit anti-human TNF alpha antibody in healthy Chinese adults. International Immunopharmacology, 2019, 75, 105807	1.7	3